<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To determine the risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> after screening with flexible sigmoidoscopy </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN: Randomised controlled trial </plain></SENT>
<SENT sid="2" pm="."><plain>SETTING: Population based screening in two areas in Norway-city of Oslo and Telemark county (urban and mixed urban and rural populations) </plain></SENT>
<SENT sid="3" pm="."><plain>PARTICIPANTS: 55 736 men and women aged 55-64 years </plain></SENT>
<SENT sid="4" pm="."><plain>INTERVENTION: Once only flexible sigmoidoscopy screening with or without a single round of faecal occult blood testing (n=13 823) compared with no screening (n=41 913) </plain></SENT>
<SENT sid="5" pm="."><plain>MAIN OUTCOME MEASURES: Planned end points were cumulative incidence and mortality of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> after 5, 10, and 15 years </plain></SENT>
<SENT sid="6" pm="."><plain>This first report from the study presents cumulative incidence after 7 years of follow-up and hazard ratio for mortality after 6 years </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: No difference was found in the 7 year cumulative incidence of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> between the screening and control groups (134.5 v 131.9 cases per 100 000 person years) </plain></SENT>
<SENT sid="8" pm="."><plain>In intention to screen analysis, a trend towards reduced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> mortality was found (hazard ratio 0.73, 95% confidence interval 0.47 to 1.13, P=0.16) </plain></SENT>
<SENT sid="9" pm="."><plain>For attenders compared with controls, a statistically significant reduction in mortality was apparent for both total <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (hazard ratio 0.41, 0.21 to 0.82, P=0.011) and rectosigmoidal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (0.24, 0.08 to 0.76, P=0.016) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: A reduction in incidence of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> with flexible sigmoidoscopy screening could not be shown after 7 years' follow-up </plain></SENT>
<SENT sid="11" pm="."><plain>Mortality from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> was not significantly reduced in the screening group but seemed to be lower for attenders, with a reduction of 59% for any location of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and 76% for rectosigmoidal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in per protocol analysis, an analysis prone to selection bias </plain></SENT>
<SENT sid="12" pm="."><plain>TRIAL REGISTRATION: Clinical trials NCT00119912 </plain></SENT>
</text></document>